We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info . X close

Ophthalmology Drugs Market Size, Growth, Share & Trends Analysis

Report Code PH 9404
Published in Jun, 2025, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Ophthalmology Drugs Market by Molecule (Faricimab, Aflibercept, Ranibizumab), Modality (Monoclonal Antibodies & Fusion Proteins), RoA (Intravitreal, Topical), Indication (AMD, Diabetic Retinopathy (DR), DME), End User - Global Forecast to 2030

Ophthalmology Drugs Market Size, Growth Drivers & Restraints

The global ophthalmology drugs market, valued at US$18.34 billion in 2024, stood at US$19.52 billion in 2025 and is projected to advance at a resilient CAGR of 6.1% from 2025 to 2030, culminating in a forecasted valuation of US$26.28 billion by the end of the period. This growth is driven by several key factors, including an increasing population affected by eye conditions, a strong pipeline of drugs being developed for ophthalmology indications, rising investments and strategic collaborations for innovation, and advancements in therapy development against ophthalmological indications. However, challenges such as the off-label use of medications and non-adherence to intravitreal injection treatments may restrain market growth during the forecast period.

Ophthalmology Drugs Market – Global Forecast and Key Opportunities to 2030

Attractive Opportunities in the Ophthalmology Drugs Market

North America

Growth in the North American ophthalmology drugs market can be attributed to increasing funding and investments in novel drug development and the presence of an established pharmaceutical infrastructure in the region.

Growth in the global ophthalmology drugs market is mainly driven by factors such as an increasing aging population and growing prevalence of vision disorders.

Shifting focus on new drug modalities and high unmet needs in this therapeutic area are some of the key opportunities for players in the ophthalmology drugs market.

The off-label use of drugs for various indications might restrain market growth.

North America is expected to be the largest market for ophthalmology drugs in 2030.

Global Ophthalmology Drugs Market Dynamics

DRIVER: Aging population and rising prevalence of vision disorders

The aging global population is one of the key factors driving the growing burden of ophthalmic diseases. As people age, they become more susceptible to conditions such as age-related macular degeneration (AMD), glaucoma, and cataracts. AMD, in particular, is a leading cause of blindness among the elderly. The increasing incidence of AMD propels the demand for anti-VEGF (vascular endothelial growth factor) therapies. Pharmaceutical companies like Regeneron and Roche leverage this trend by offering blockbuster treatments such as Eylea (aflibercept) and Lucentis (ranibizumab). These drugs work by targeting VEGF, a protein responsible for abnormal blood vessel growth in wet AMD. More recently, Roche/Genentech introduced Vabysmo (faricimab), a dual-action therapy that inhibits both VEGF-A and Ang-2. This innovation not only improves durability but also reduces the frequency of injections, thereby enhancing patient convenience. AMD is a major cause of vision loss, particularly in older adults. While aging remains a significant risk factor, lifestyle choices also play an increasingly important role in its prevalence. A recent meta-analysis covering Europe, Australia, and the US found a sharp rise in late-stage AMD—from 0.3 to 36.7 cases per 1,000 individuals aged 55–59 and 90 or older, respectively. Late-stage AMD also has a high heritability estimate of 71%, suggesting a strong genetic component. In 2023, collaborative research by teams from the US and Europe identified specific gene variants closely linked to AMD. Notably, three out of six genes also associated with central serous chorioretinopathy (CSC) were found to contribute to AMD, underscoring the complex genetic factors behind this vision-threatening condition.

RESTRAINT: Off-label drug use across multiple ophthalmic indications

In ophthalmology, key therapeutic areas include age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR). A major challenge for drug developers in this space is the widespread use of off-label medications, which can limit new product uptake and revenue generation. One prominent example is bevacizumab (Avastin), which, although originally approved for cancer treatment, is frequently used off-label to manage AMD, DME, and DR due to its significantly lower cost. Avastin’s structural similarity to the FDA-approved AMD therapy Lucentis (ranibizumab) further supports its use as a cost-effective alternative. The price difference between the two drugs is particularly striking. This substantial economic benefit is a key driver of Avastin’s widespread off-label use. Outlook Therapeutics, a US-based clinical-stage biotechnology company, has received EMA approval for Lytenava, an ophthalmic formulation of bevacizumab. Off-label Avastin use currently accounts for nearly 50% of the wet AMD market in the US, underscoring its strong clinical presence. Its widespread use is backed by numerous studies that demonstrate its efficacy in treating AMD and other retinal diseases. Government agencies have also lent support. For instance, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) conducted in the US and funded by NIH confirmed that Avastin is equally effective as Lucentis in treating subfoveal neovascular AMD. These findings have helped normalize Avastin's use in many countries, with some even offering insurance coverage for it exclusively in AMD treatment. However, Avastin is not without concerns. Follow-up studies have raised questions about its safety profile compared to Lucentis. Despite this, Avastin remains widely used in major markets such as the US and is covered under Medicare Part B for AMD treatment. In the EU, the European Court of Justice upheld Italy’s 2018 decision to include Avastin’s off-label use for wet AMD in national reimbursement lists, reinforcing its acceptance at both clinical and policy levels.

 

OPPORTUNITY: Shifting focus to new drug modalities

The primary treatment options for ophthalmic conditions today largely consist of monoclonal antibodies and recombinant fusion proteins such as Lucentis, Eylea, Beovu, Susvimo, and the recently approved Lytenava. Despite their clinical effectiveness, these therapies present significant limitations, including the need for frequent injections, high costs, and patient discomfort. For instance, Eylea—a recombinant fusion protein—is used to manage age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR), with a single dose costing approximately USD 1,800. Lucentis, another widely used monoclonal antibody for AMD, DME, and retinal vein occlusion (RVO), requires administration every four weeks to maintain its therapeutic effect. Even with regular treatment, outcomes are often suboptimal. Data from Opthea Limited shows that 45% of patients receiving anti-VEGF therapies do not achieve significant visual improvements, and around 25% may experience further vision loss within a year or more of treatment. These challenges have intensified research efforts into novel treatment modalities such as gene therapies, hydrogels, and oral delivery systems. Gene therapy, in particular, holds promise for long-lasting treatment by delivering therapeutic genes directly to retinal cells, potentially eliminating the need for frequent injections. One such example is Adverum Biotechnologies’ leading gene therapy candidate, Ixoberogene soroparvovec (Ixo-vec), which is currently in Phase III clinical trials initiated in March 2025. Ixo-vec is designed as a one-time intravitreal (IVT) injection aimed at restoring vision and halting the progression of blindness in wet AMD. Meanwhile, hydrogels are being studied for their potential to enable sustained and controlled drug release, which could enhance treatment adherence and reduce dosing frequency.

CHALLENGES: Frequent and inconvenient intravitreal injections

One of the most pressing challenges in managing ophthalmologic conditions such as age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), and retinal vein occlusion (RVO) is ensuring patient adherence to treatment. These conditions are typically treated using intravitreal injections, particularly anti-VEGF therapies. However, the need for frequent administration has become a major deterrent to long-term compliance. A 2021 multi-country research study involving patients from the UK, Australia, Brazil, and Canada revealed that non-adherence and early discontinuation of anti-VEGF treatments for neovascular AMD (nAMD) are significant obstacles to achieving effective outcomes. According to the study, nearly half of all patients stopped treatment within two years, with non-adherence rates ranging widely between 32% and 95%. These findings are echoed in insights from ophthalmologists across the UAE, UK, and India, who reported that the primary reasons for poor adherence include the burdensome frequency of injections, the need for regular clinic or hospital visits, and the associated financial costs. Additionally, a patient's level of education can also impact their understanding and commitment to consistent treatment, further contributing to dropout rates. Further evidence comes from a 2023 survey by the Norwegian subsidiary of F. Hoffmann-La Roche AG, conducted in collaboration with the University of Oslo. The survey found that nearly 49% of patients in Norway required nine or more intravitreal injections each year. Alarmingly, 37.7% of these patients also required caregiver support for each injection, highlighting the physical, emotional, and logistical burden placed on both patients and families.

Global Ophthalmology Drugs Market Ecosystem Analysis

The ophthalmology drugs market ecosystem consists of several key stakeholders. Raw material suppliers provide essential components, including consumables like media and reagents. End users include hospitals, specialty clinics, and long-term care facilities. Pharmaceutical and biotechnology companies are responsible for developing and distributing ophthalmology drugs while adhering to regulations set by organizations such as the FDA and EMA. This ensures quality and compliance throughout the supply chain. These stakeholders interact and collaborate effectively, facilitating the research and development of biopharmaceuticals and driving advancements in the creation of novel ophthalmologic drugs.

Ophthalmology Drugs Market
 

Aflibercept commanded the largest market share in 2024.

On the basis of molecules, the ophthalmology drugs market is segmented into aflibercept, faricimab, ranibizumab, and other molecules. The aflibercept segment holds the largest market share due to its widespread adoption for treating various ophthalmic conditions and its significant geographic reach. Aflibercept, marketed under brands like Eylea and Eylea HD, is widely used for treating retinal diseases such as age-related macular degeneration (AMD), diabetic eye disease, and retinal vein occlusion. It is a recombinant fusion protein that blocks vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), both of which contribute to abnormal blood vessel formation and leakage in the eye. Factors such as exceptionally high binding strength, allowing aflibercept to prevent VEGF from activating its receptors and reduce vascular leakage, set it apart from other anti-VEGF drugs. Its small molecular size enhances its penetration into the retina and choroid, enabling better treatment outcomes with fewer injections. A 2024 clinical study from Brazil reinforced its superior performance. Compared to other treatments like ranibizumab, bevacizumab, and ziv-aflibercept, patients receiving aflibercept required fewer injections and experienced improved retinal structure. Thus, aflibercept’s strong efficacy, fewer required doses, and improved patient outcomes make it a preferred treatment option for retinal diseases. Its advantages are expected to drive market adoption, reduce patient burden, and improve healthcare efficiency.

By indication, AMD accounted for the largest market share in 2024.

Based on indication, the ophthalmology drugs market is categorized into several segments, including age-related macular degeneration (both dry and wet forms), diabetic retinopathy, diabetic macular edema, and other indications. In 2024, the age-related macular degeneration segment accounted for the largest share of the market. Increasing research and treatment options, as well as a rising prevalence of the disease, are some of the key factors supporting the large share of this segment. AMD significantly impacts the quality of life, often progressing to severe vision impairment if left untreated. The disease’s chronic nature demands ongoing management, driving sustained demand for therapies, particularly anti-VEGF drugs like aflibercept, ranibizumab, and bevacizumab. Additionally, advancements in diagnostics and heightened awareness lead to earlier detection and intervention, further expanding the treatment pool. The growing elderly population, combined with AMD’s chronic progression and need for repeated treatment, positions it as the dominant driver of the ophthalmic drugs market, fueling innovation and market growth.

North America commanded the largest regional share in the ophthalmology drugs market in 2024.

North America has established itself as the largest market for ophthalmology drugs, driven by a combination of demographic, economic, and healthcare factors. The region has a rapidly aging population, leading to a higher prevalence of age-related eye conditions such as AMD, diabetic retinopathy, and glaucoma. Additionally, North America boasts a highly developed healthcare infrastructure with widespread access to advanced diagnostics and treatment options. High awareness levels among patients and physicians promote early diagnosis and consistent treatment. The presence of leading pharmaceutical companies and active clinical research in the region also accelerates the development and adoption of innovative ophthalmic therapies. Favorable reimbursement policies, particularly in the US under Medicare, further enhance patient access to costly treatments like anti-VEGF injections. Moreover, regulatory support and fast-track approvals by the FDA contribute to the timely introduction of new drugs. Thus, North America’s strong healthcare ecosystem, high disease burden, and supportive policy environment make it the leading region in the global ophthalmology drugs market.

NORTH AMERICA COMMANDED HIGHEST MARKET SHARE IN 2024
US IS FASTEST-GROWING MARKET IN NORTH AMERICA
Ophthalmology Drugs Market Region

Recent Developments of Ophthalmology Drugs Market

  • Collaboration: In February 2025, Teva entered into a strategic collaboration with Klinge Biopharma and Formycon to commercialize FYB203, a biosimilar candidate for Eylea (aflibercept), in most parts of Europe (excluding Italy) and Israel. The biosimilar, branded as AHZANTIVE, is developed by Formycon and has been in-licensed by Klinge for global commercialization.
  • Agreement: In September 2022, Outlook Therapeutics, Inc. entered into a strategic agreement with Cencora for the commercial launch of Lytenava in the US after the drug was approved by the US Food and Drug Administration (FDA). Cencora will offer third-party logistics services and distribution, as well as medical information and pharmacovigilance services in the US.
  • Product Approval: In December 2024, Roche received approval from the European Medicines Agency for its Vabysmo (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for the treatment of patients with neovascular or wet age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). Vabysmo PFS will be the European Union’s first and only prefilled syringe containing a bispecific antibody to treat retinal conditions that can cause blindness.
  • Product Launch: In March 2024, Roche Products (India) Pvt. Ltd., an Indian subsidiary of F. Hoffmann-La Roche Ltd., launched Vabysmo in the Indian market for the treatment of neovascular or wet age-related macular degeneration (nAMD) and diabetic macular edema (DME).

Key Market Players

Want to explore hidden markets that can drive new revenue in Ophthalmology Drugs Market?

Scope of the Report

Report Metric Details
Market size available for years 2023-2030
Base Year Considered 2024
Forecast period 2025-2030
Forecast units Value (USD)
Segments covered Molecule, Modality, Indication, Route of Administration, End user
Geographies covered North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa

Key Questions Addressed by the Report

Who are the key players in the ophthalmology drugs market?

The key players include Regeneron Pharmaceuticals, Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Bayer AG (Germany), and Novartis AG (Switzerland).

Which molecule segment dominates the ophthalmology drugs market?

Aflibercept dominates the market due to its high efficacy and high adoption.

Which indication segment dominated the market in 2024?

The AMD segment dominated in 2024, driven by the rising prevalence of AMD and high adoption of anti-VEGF drugs.

Which regional segment of the ophthalmology drugs market accounted for the largest market share in 2024?

North America held the largest market share in 2024, supported by a strong healthcare ecosystem, high disease burden, and a supportive policy environment.

What is the size and growth rate of the ophthalmology drugs market?

The market is projected to reach USD 26.28 billion by 2030 from USD 19.52 billion in 2025, growing at a CAGR of 6.1%.

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Ophthalmology Drugs Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
31
RESEARCH METHODOLOGY
35
EXECUTIVE SUMMARY
47
PREMIUM INSIGHTS
51
MARKET OVERVIEW
54
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Aging population and growing prevalence of vision disorders
    - Strong drug pipeline and growing innovation efforts
    - Increasing investments and strategic collaborations
    - Improved reimbursement policies
    RESTRAINTS
    - Off-label drug use for various indications
    OPPORTUNITIES
    - Shifting focus on new drug modalities
    - Expansion into emerging markets
    - High unmet needs
    CHALLENGES
    - Frequent and inconvenient intravitreal injections leading to patient non-adherence to treatment
  • 5.3 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Hybridoma technology
    - Recombinant DNA technology
    - Antibody engineering
    - Gene therapy
    - Nanoformulations
    ADJACENT TECHNOLOGIES
    - Optogenetic technology
    - Drug-release technologies
    - Ocular implant technologies
    COMPLEMENTARY TECHNOLOGIES
    - 3D printing and bioprinting
    - Ocular imaging technologies
  • 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • 5.5 PRICING ANALYSIS
    INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY MOLECULE, 2024
    INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY COUNTRY, 2024
    INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY KEY PLAYER, 2024
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
    OPHTHALMOLOGY DRUGS MARKET: ROLE OF RAW MATERIAL SUPPLIERS
    OPHTHALMOLOGY DRUGS MARKET: ROLE OF PRODUCT PROVIDERS AND PHASE III PIPELINE PRODUCT COMPANIES
    OPHTHALMOLOGY DRUGS MARKET: ROLE OF END USERS
    OPHTHALMOLOGY DRUGS MARKET: ROLE OF REGULATORY AUTHORITIES
  • 5.8 PATENT ANALYSIS
  • 5.9 REGULATORY ANALYSIS
    REGULATORY LANDSCAPE
    - US
    - Europe
    - Emerging markets
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10 PORTER’S FIVE FORCES ANALYSIS
    INTENSITY OF COMPETITIVE RIVALRY
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    THREAT OF SUBSTITUTES
    THREAT OF NEW ENTRANTS
  • 5.11 KEY CONFERENCES & EVENTS, 2025–2026
  • 5.12 REIMBURSEMENT SCENARIO
  • 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
    BUYING CRITERIA FOR OPHTHALMOLOGY DRUGS
  • 5.14 INVESTMENT & FUNDING SCENARIO
  • 5.15 PIPELINE ANALYSIS
  • 5.16 IMPACT OF ARTIFICIAL INTELLIGENCE ON OPHTHALMOLOGY DRUGS MARKET
    CHALLENGES IN DRUG DISCOVERY
    IMPACT OF AI ON DISCOVERY OF OPHTHALMOLOGY DRUGS
  • 5.17 IMPACT OF 2025 US TARIFFS ON OPHTHALMOLOGY DRUGS MARKET
    KEY TARIFF RATES
    PRICE IMPACT ANALYSIS
    KEY IMPACT ON VARIOUS REGIONS
    - US
    - Europe
    - APAC
    MANUFACTURING INDUSTRY IMPACT
    - Ophthalmology drug manufacturers
OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE
98
  • 6.1 INTRODUCTION
  • 6.2 AFLIBERCEPT
    HIGH EFFICIENCY OF AFLIBERCEPT IN TREATING RETINAL DISEASES TO DRIVE MARKET GROWTH
  • 6.3 FARICIMAB
    GROWING ADOPTION AND POSITIVE OUTCOMES OF STUDIES TO SUPPORT MARKET GROWTH
  • 6.4 RANIBIZUMAB
    CLINICAL EFFICACY OF RANIBIZUMAB TO DRIVE ADOPTION
  • 6.5 OTHER MOLECULES
OPHTHALMOLOGY DRUGS MARKET, BY MODALITY
112
  • 7.1 INTRODUCTION
  • 7.2 MONOCLONAL ANTIBODIES & FUSION PROTEINS
    GROWING FOCUS ON DEVELOPING NEW MABS TO DRIVE MARKET
  • 7.3 SMALL MOLECULES
    INCREASING INVESTMENTS AND RESEARCH TO DRIVE MARKET
  • 7.4 OTHER MODALITIES
OPHTHALMOLOGY DRUGS MARKET, BY INDICATION
123
  • 8.1 INTRODUCTION
  • 8.2 AGE-RELATED MACULAR DEGENERATION
    WET AGE-RELATED MACULAR DEGENERATION
    - Increasing demand for effective therapies to drive market
    DRY AGE-RELATED MACULAR DEGENERATION
    - Large market opportunity for innovation to drive growth
  • 8.3 DIABETIC RETINOPATHY (DR)
    FEWER APPROVED DRUGS TO PRESENT MARKET OPPORTUNITIES
  • 8.4 DIABETIC MACULAR EDEMA (DME)
    GROWING ADOPTION OF APPROVED ANTI-VEGF DRUGS FOR DME TO DRIVE MARKET
  • 8.5 OTHER INDICATIONS
OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION
139
  • 9.1 INTRODUCTION
  • 9.2 INTRAVITREAL
    HIGH EFFICACY OF INTRAVITREAL INJECTIONS IN TREATMENT OF MAJOR RETINAL DISEASES TO DRIVE MARKET
  • 9.3 TOPICAL
    EASE OF USE TO DRIVE DEMAND FOR TOPICAL DRUGS
  • 9.4 OTHER ROUTES OF ADMINISTRATION
OPHTHALMOLOGY DRUGS MARKET, BY END USER
148
  • 10.1 INTRODUCTION
  • 10.2 HOSPITALS
    GROWING COLLABORATIONS BETWEEN HOSPITALS AND PHARMACEUTICAL COMPANIES TO ENCOURAGE GROWTH
  • 10.3 LONG-TERM CARE FACILITIES
    NEED FOR SUSTAINED MEDICAL SUPERVISION AND SUPPORT FOR CHRONIC CONDITIONS TO FUEL MARKET
  • 10.4 SPECIALTY CENTERS
    RISING INCLINATION TOWARD PERSONALIZED TREATMENT PLANS TO ACCELERATE GROWTH
OPHTHALMOLOGY DRUGS MARKET, BY REGION
158
  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - Rising investments in healthcare research and development to support growth
    CANADA
    - Rising government initiatives to support ophthalmology drugs research and increasing drug approvals to support growth
  • 11.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - Rising focus on clinical research to drive market
    UK
    - Ongoing advancements in technology to drive market growth
    FRANCE
    - Growing investments and government support to drive market growth
    ITALY
    - Growing investments and research to support market
    SPAIN
    - Growing geriatric population to drive market growth
    REST OF EUROPE
  • 11.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    - Large diabetic population to boost market
    JAPAN
    - Growing aging population to intensify demand for effective treatments
    INDIA
    - Increasing diabetic cases, government support, and growing availability of biosimilars to support market
    AUSTRALIA
    - Strong biopharmaceutical sector to drive market growth
    SOUTH KOREA
    - Strong R&D pipeline and increasing focus on research to support growth
    REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Significant rates of visual impairment in region to drive demand for advanced treatments
    MEXICO
    - Growing research initiatives and innovations to support market growth
    REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    GCC COUNTRIES
    - Growing research initiatives and improving healthcare infrastructure to support growth
    REST OF MIDDLE EAST
  • 11.7 AFRICA
    GROWING FOCUS ON HEALTHCARE TO DRIVE MARKET GROWTH
    MACROECONOMIC OUTLOOK FOR AFRICA
COMPETITIVE LANDSCAPE
237
  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN OPHTHALMOLOGY DRUGS MARKET
  • 12.3 REVENUE ANALYSIS, 2022–2024
  • 12.4 MARKET SHARE ANALYSIS, 2024
  • 12.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS, 2024
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2024
    - Company footprint
    - Region footprint
    - Molecule footprint
    - Modality footprint
    - Indication footprint
  • 12.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    - Detailed list of key startups/SMEs
    - Competitive benchmarking of startups/SMEs
  • 12.7 COMPANY VALUATION & FINANCIAL METRICS
    VALUATION OF KEY PLAYERS
    FINANCIAL METRICS OF KEY PLAYERS
  • 12.8 BRAND/PRODUCT COMPARISON
  • 12.9 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES & APPROVALS
    DEALS
COMPANY PROFILES
257
  • 13.1 KEY PLAYERS
    REGENERON PHARMACEUTICALS INC.
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    F. HOFFMANN-LA ROCHE LTD.
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    BAYER AG
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    NOVARTIS AG
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    ABBVIE
    - Business overview
    - Products offered
    APELLIS PHARMACEUTICALS
    - Business overview
    - Products offered
    - Recent developments
    BIOGEN
    - Business overview
    - Products offered
    - Recent developments
    BAUSCH + LOMB
    - Business overview
    - Products offered
    - Recent developments
    ASTELLAS PHARMA INC.
    - Business overview
    - Products offered
    - Recent developments
    FORMYCON AG
    - Business overview
    - Products offered
    - Recent developments
    BIOCON
    - Business overview
    - Products offered
    - Recent developments
    SANDOZ GROUP AG
    - Business overview
    - Products offered
    - Recent developments
    SANTEN PHARMACEUTICAL CO., LTD.
    - Business overview
    - Products offered
    - Recent developments
    INNOVENT
    - Business overview
    - Products offered
    - Recent developments
    OUTLOOK THERAPEUTICS, INC.
    - Business overview
    - Products offered
    - Recent developments
    TEVA PHARMACEUTICAL INDUSTRIES LTD.
    - Business overview
    - Products offered
    - Recent developments
  • 13.2 OTHER PLAYERS (PIPELINE COMPANIES)
    OCULAR THERAPEUTIX, INC.
    OPTHEA LIMITED
    KODIAK SCIENCES INC.
    EYEPOINT PHARMACEUTICALS, INC.
    ALVOTECH
    CLEARSIDE BIOMEDICAL
    SHANGHAI HENLIUS BIOTECH, INC.
    ADVERUM BIOTECHNOLOGIES, INC.
    REMEGEN
    SPARINGVISION
APPENDIX
321
  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
  • TABLE 2 OPHTHALMOLOGY DRUGS MARKET: RISK ANALYSIS
  • TABLE 3 OPHTHALMOLOGY DRUGS MARKET: IMPACT ANALYSIS
  • TABLE 4 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY MOLECULE, 2024
  • TABLE 5 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY KEY PLAYER, 2024
  • TABLE 6 OPHTHALMOLOGY DRUGS MARKET: LIST OF RAW MATERIAL SUPPLIERS
  • TABLE 7 OPHTHALMOLOGY DRUGS MARKET: LIST OF PRODUCT PROVIDERS AND PHASE III PIPELINE PRODUCT COMPANIES
  • TABLE 8 OPHTHALMOLOGY DRUGS MARKET: LIST OF END USERS
  • TABLE 9 OPHTHALMOLOGY DRUGS MARKET: LIST OF REGULATORY AUTHORITIES
  • TABLE 10 OPHTHALMOLOGY DRUGS MARKET: INDICATIVE LIST OF PATENTS, 2024
  • TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 OPHTHALMOLOGY DRUGS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 17 OPHTHALMOLOGY DRUGS MARKET: LIST OF CONFERENCES & EVENTS
  • TABLE 18 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%)
  • TABLE 19 BUYING CRITERIA FOR OPHTHALMOLOGY DRUGS, BY END USER
  • TABLE 20 OPHTHALMOLOGY DRUGS IN CLINICAL PIPELINE, PHASE III (AS OF APRIL 2025)
  • TABLE 21 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 22 EXPORTS AND IMPORTS, BY REGION
  • TABLE 23 OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 24 OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 25 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 26 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 27 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 28 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 29 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 30 OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 31 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 32 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 33 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 34 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 35 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 36 OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 37 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 38 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 39 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 40 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 41 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 42 OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 43 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 44 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 45 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 46 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 47 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 48 OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
  • TABLE 49 OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 50 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 51 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 52 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 53 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 54 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 55 OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 56 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 57 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 58 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 59 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 60 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 61 OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 62 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 63 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 64 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 65 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 66 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 67 OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 68 OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 69 OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 70 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 71 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 72 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 73 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 74 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 75 OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 76 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 77 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 78 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 79 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 80 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 81 OPHTHALMOLOGY DRUGS MARKET FOR DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 82 OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC RETINOPATHY, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 83 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC RETINOPATHY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 84 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC RETINOPATHY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 85 OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 86 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 87 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 89 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 90 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 91 OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 92 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 93 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 94 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 95 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 96 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 97 OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 98 OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 99 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 100 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 101 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 102 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 103 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 104 OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 105 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 106 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 107 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 108 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 109 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 110 OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 111 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 112 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 113 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 114 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 115 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 116 OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 117 OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 118 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 119 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 120 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 121 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 122 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 123 OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 124 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 125 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 126 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 127 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 128 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 129 OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 130 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 131 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 132 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 133 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 134 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 135 OPHTHALMOLOGY DRUGS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 136 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 137 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 138 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 139 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
  • TABLE 140 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 141 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 142 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 143 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 144 US: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 145 US: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
  • TABLE 146 US: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 147 US: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 148 US: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 149 US: OPHTHALMOLOGY DRUGS MARKET, BY END USER,2023–2030 (USD MILLION)
  • TABLE 150 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 151 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
  • TABLE 152 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 153 CANADA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 154 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 155 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 156 EUROPE: MACROECONOMIC INDICATORS
  • TABLE 157 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 158 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 159 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
  • TABLE 160 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 161 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 162 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 163 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 164 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 165 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
  • TABLE 166 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 167 GERMANY: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 168 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 169 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 170 UK: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 171 UK: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
  • TABLE 172 UK: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 173 UK: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 174 UK: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 175 UK: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 176 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 177 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
  • TABLE 178 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 179 FRANCE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 180 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 181 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 182 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 183 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
  • TABLE 184 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 185 ITALY: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 186 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 187 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 188 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 189 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
  • TABLE 190 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 191 SPAIN: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 192 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 193 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 194 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 195 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
  • TABLE 196 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 197 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 198 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 199 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 200 ASIA PACIFIC: MACROECONOMIC INDICATORS
  • TABLE 201 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 202 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 203 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
  • TABLE 204 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 205 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 206 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 207 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 208 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 209 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
  • TABLE 210 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 211 CHINA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 212 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 213 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 214 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 215 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
  • TABLE 216 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 217 JAPAN: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 218 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 219 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 220 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 221 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
  • TABLE 222 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 223 INDIA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 224 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 225 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 226 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 227 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
  • TABLE 228 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 229 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 230 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 231 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 232 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 233 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
  • TABLE 234 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 235 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 236 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 237 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 238 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 239 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
  • TABLE 240 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 241 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 242 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 243 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 244 LATIN AMERICA: MACROECONOMIC INDICATORS
  • TABLE 245 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 246 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 247 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
  • TABLE 248 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 249 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 250 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 251 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 252 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 253 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
  • TABLE 254 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 255 BRAZIL: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 256 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 257 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 258 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 259 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
  • TABLE 260 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 261 MEXICO: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 262 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 263 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 264 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 265 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
  • TABLE 266 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 267 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 268 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 269 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 270 MIDDLE EAST: MACROECONOMIC INDICATORS
  • TABLE 271 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 272 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY,2023–2030 (USD MILLION)
  • TABLE 273 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 274 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 275 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 276 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 277 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 278 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
  • TABLE 279 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 280 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 281 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 282 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 283 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 284 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
  • TABLE 285 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 286 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 287 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 288 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 289 AFRICA: MACROECONOMIC INDICATORS
  • TABLE 290 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
  • TABLE 291 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
  • TABLE 292 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
  • TABLE 293 AFRICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 294 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
  • TABLE 295 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 296 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN OPHTHALMOLOGY DRUGS MARKET
  • TABLE 297 OPHTHALMOLOGY DRUGS MARKET: DEGREE OF COMPETITION
  • TABLE 298 OPHTHALMOLOGY DRUGS MARKET: REGION FOOTPRINT
  • TABLE 299 OPHTHALMOLOGY DRUGS MARKET: MOLECULE FOOTPRINT
  • TABLE 300 OPHTHALMOLOGY DRUGS MARKET: MODALITY FOOTPRINT
  • TABLE 301 OPHTHALMOLOGY DRUGS MARKET: INDICATION FOOTPRINT
  • TABLE 302 OPHTHALMOLOGY DRUGS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 303 OPHTHALMOLOGY DRUGS MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
  • TABLE 304 OPHTHALMOLOGY DRUGS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–MAY 2025
  • TABLE 305 OPHTHALMOLOGY DRUGS MARKET: DEALS, JANUARY 2022–MAY 2025
  • TABLE 306 REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW
  • TABLE 307 REGENERON PHARMACEUTICALS INC.: PRODUCTS OFFERED
  • TABLE 308 REGENERON PHARMACEUTICALS INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2025
  • TABLE 309 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 310 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
  • TABLE 311 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025
  • TABLE 312 BAYER AG: COMPANY OVERVIEW
  • TABLE 313 BAYER AG: PRODUCTS OFFERED
  • TABLE 314 BAYER AG: PRODUCT APPROVALS, JANUARY 2021–MAY 2025
  • TABLE 315 NOVARTIS AG: COMPANY OVERVIEW
  • TABLE 316 NOVARTIS AG: PRODUCTS OFFERED
  • TABLE 317 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2021–MAY 2025
  • TABLE 318 NOVARTIS AG: DEALS, JANUARY 2021–MAY 2025
  • TABLE 319 ABBVIE: COMPANY OVERVIEW
  • TABLE 320 ABBVIE: PRODUCTS OFFERED
  • TABLE 321 APELLIS PHARMACEUTICALS: COMPANY OVERVIEW
  • TABLE 322 APELLIS PHARMACEUTICALS: PRODUCTS OFFERED
  • TABLE 323 APELLIS PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY 2021–MAY 2025
  • TABLE 324 APELLIS PHARMACEUTICALS: DEALS, JANUARY 2021–MAY 2025
  • TABLE 325 BIOGEN: COMPANY OVERVIEW
  • TABLE 326 BIOGEN: PRODUCTS OFFERED
  • TABLE 327 BIOGEN: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025
  • TABLE 328 BAUSCH + LOMB: COMPANY OVERVIEW
  • TABLE 329 BAUSCH + LOMB: PRODUCTS OFFERED
  • TABLE 330 BAUSCH + LOMB: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025
  • TABLE 331 ASTELLAS PHARMA INC.: COMPANY OVERVIEW
  • TABLE 332 ASTELLAS PHARMA INC.: PRODUCTS OFFERED
  • TABLE 333 ASTELLAS PHARMA INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2025
  • TABLE 334 ASTELLAS PHARMA INC.: DEALS, JANUARY 2021–JULY 2024
  • TABLE 335 FORMYCON AG: COMPANY OVERVIEW
  • TABLE 336 FORMYCON AG: PRODUCTS OFFERED
  • TABLE 337 FORMYCON AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025
  • TABLE 338 FORMYCON AG: DEALS, JANUARY 2021–MAY 2025
  • TABLE 339 BIOCON: COMPANY OVERVIEW
  • TABLE 340 BIOCON: PRODUCTS OFFERED
  • TABLE 341 BIOCON: PRODUCT APPROVALS, JANUARY 2021–MAY 2025
  • TABLE 342 BIOCON: DEALS, JANUARY 2021–MAY 2025
  • TABLE 343 SANDOZ GROUP AG: COMPANY OVERVIEW
  • TABLE 344 SANDOZ GROUP AG: PRODUCTS OFFERED
  • TABLE 345 SANDOZ GROUP AG: PRODUCT APPROVALS, JANUARY 2021–MAY 2025
  • TABLE 346 SANDOZ GROUP AG: DEALS, JANUARY 2021–JULY 2024
  • TABLE 347 SANTEN PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW
  • TABLE 348 SANTEN PHARMACEUTICALS CO., LTD.: PRODUCTS OFFERED
  • TABLE 349 SANTEN PHARMACEUTICAL CO., LTD: PRODUCT LAUNCHES, JANUARY 2021–MAY 2025
  • TABLE 350 INNOVENT: COMPANY OVERVIEW
  • TABLE 351 INNOVENT: PRODUCTS OFFERED
  • TABLE 352 INNOVENT: PRODUCT APPROVALS, JANUARY 2021–MAY 2025
  • TABLE 353 OUTLOOK THERAPEUTICS, INC.: COMPANY OVERVIEW
  • TABLE 354 OUTLOOK THERAPEUTICS, INC.: PRODUCTS OFFERED
  • TABLE 355 OUTLOOK THERAPEUTICS, INC.: PRODUCT APPROVALS, JANUARY 2022–MAY 2025
  • TABLE 356 OUTLOOK THERAPEUTICS, INC.: DEALS, JANUARY 2022–MAY 2025
  • TABLE 357 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
  • TABLE 358 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
  • TABLE 359 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT APPROVALS, JANUARY 2022–MAY 2025
  • TABLE 360 TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2022–MAY 2025
  • TABLE 361 OCULAR THERAPEUTIX, INC.: COMPANY OVERVIEW
  • TABLE 362 OPTHEA LIMITED: COMPANY OVERVIEW
  • TABLE 363 KODIAK SCIENCES INC.: COMPANY OVERVIEW
  • TABLE 364 EYEPOINT PHARMACEUTICALS, INC.: COMPANY OVERVIEW
  • TABLE 365 ALVOTECH: COMPANY OVERVIEW
  • TABLE 366 CLEARSIDE BIOMEDICAL: COMPANY OVERVIEW
  • TABLE 367 SHANGHAI HENLIUS BIOTECH, INC.: COMPANY OVERVIEW
  • TABLE 368 ADVERUM BIOTECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 369 REMEGEN: COMPANY OVERVIEW
  • TABLE 370 SPARINGVISION: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 OPHTHALMOLOGY DRUGS MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 OPHTHALMOLOGY DRUGS MARKET: RESEARCH DESIGN
  • FIGURE 3 OPHTHALMOLOGY DRUGS MARKET: KEY DATA FROM SECONDARY SOURCES
  • FIGURE 4 OPHTHALMOLOGY DRUGS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
  • FIGURE 5 OPHTHALMOLOGY DRUGS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
  • FIGURE 6 PRODUCT REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH (2024)
  • FIGURE 7 REVENUE SHARE ANALYSIS OF REGENERON PHARMACEUTICALS, INC. (2024)
  • FIGURE 8 OPHTHALMOLOGY DRUGS MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 9 OPHTHALMOLOGY DRUGS MARKET: BOTTOM-UP APPROACH
  • FIGURE 10 OPHTHALMOLOGY DRUGS MARKET: CAGR PROJECTIONS
  • FIGURE 11 OPHTHALMOLOGY DRUGS MARKET: DATA TRIANGULATION
  • FIGURE 12 OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 13 OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 16 OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 17 GEOGRAPHIC ANALYSIS: OPHTHALMOLOGY DRUGS MARKET
  • FIGURE 18 GROWING PREVALENCE OF RETINAL DISEASES AND INCREASING R&D INVESTMENTS TO DRIVE MARKET GROWTH
  • FIGURE 19 AFLIBERCEPT ACCOUNTED FOR LARGEST SHARE OF OPHTHALMOLOGY DRUGS MARKET IN NORTH AMERICA IN 2024
  • FIGURE 20 HOSPITALS TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 21 NORTH AMERICA LIKELY TO BE FASTEST-GROWING MARKET IN GLOBAL OPHTHALMOLOGY DRUGS MARKET DURING FORECAST PERIOD
  • FIGURE 22 OPHTHALMOLOGY DRUGS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 23 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • FIGURE 24 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY COUNTRY, 2024
  • FIGURE 25 OPHTHALMOLOGY DRUGS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 26 OPHTHALMOLOGY DRUGS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 27 OPHTHALMOLOGY DRUGS MARKET: PATENT PUBLICATION TRENDS, JURISDICTION, AND TOP APPLICANT ANALYSIS (JANUARY 2014–DECEMBER 2024)
  • FIGURE 28 OPHTHALMOLOGY DRUGS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 29 KEY STAKEHOLDERS IN BUYING PROCESS OF OPHTHALMOLOGY DRUGS, BY MODALITY
  • FIGURE 30 KEY BUYING CRITERIA FOR END USERS
  • FIGURE 31 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET SNAPSHOT
  • FIGURE 32 EUROPE: OPHTHALMOLOGY DRUGS MARKET SNAPSHOT
  • FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS, 2022–2024 (USD MILLION)
  • FIGURE 34 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024
  • FIGURE 35 OPHTHALMOLOGY DRUGS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 36 OPHTHALMOLOGY DRUGS MARKET: COMPANY FOOTPRINT
  • FIGURE 37 OPHTHALMOLOGY DRUGS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 38 EV/EBITDA OF KEY PLAYERS
  • FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY PLAYERS
  • FIGURE 40 OPHTHALMOLOGY DRUGS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 41 REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 42 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
  • FIGURE 43 BAYER AG: COMPANY SNAPSHOT (2024)
  • FIGURE 44 NOVARTIS AG: COMPANY SNAPSHOT (2024)
  • FIGURE 45 ABBVIE: COMPANY SNAPSHOT (2024)
  • FIGURE 46 APELLIS PHARMACEUTICALS: COMPANY SNAPSHOT (2024)
  • FIGURE 47 BIOGEN: COMPANY SNAPSHOT (2024)
  • FIGURE 48 BAUSCH + LOMB: COMPANY SNAPSHOT (2024)
  • FIGURE 49 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 50 FORMYCON AG: COMPANY SNAPSHOT (2024)
  • FIGURE 51 BIOCON: COMPANY SNAPSHOT (2024)
  • FIGURE 52 SANDOZ GROUP AG: COMPANY SNAPSHOT (2024)
  • FIGURE 53 SANTEN PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT (2024)
  • FIGURE 54 INNOVENT: COMPANY SNAPSHOT (2024)
  • FIGURE 55 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024)

 

This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global ophthalmology drugs market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the ophthalmology drugs market. The secondary sources used for this study include US Food and Drug Administration (US FDA), European Medicines Agency (EMA), World Health Organization (WHO), National Center for Biotechnology Information (NCBI), White papers, Company Websites, Interviews with Experts, Annual Reports, SEC Filings, Investor Presentations, and MarketsandMarkets Analysis. These sources also obtained key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

A comprehensive primary research was undertaken following an initial assessment of the global ophthalmology drugs market landscape through secondary research. This involved conducting in-depth interviews with market experts from the demand side, including stakeholders from hospitals, long-term care facilities, and specialty centers. Additionally, interviews were held with key supply-side participants, such as C-suite and senior executives, product managers, and marketing and sales leaders from prominent manufacturers, distributors, and channel partners. The research covered six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% involved demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephonic discussions to understand the market dynamics comprehensively.

The following is a breakdown of the primary respondents:

Ophthalmology Drugs Market

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both bottom-up and top-down approaches were used to estimate and validate the total size of the ophthalmology drugs market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • A list of the major global players operating in the ophthalmology drugs market was generated.
  • The revenues generated from their ophthalmology drug products have been determined through annual reports and secondary sources (including paid databases).
  • The products were mapped according to the segments of the market. Percentage shares and splits were determined based on the revenue contributed to each segment. This was verified using secondary sources and by industry experts.
  • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

Global Ophthalmology Drugs Market Size: Bottom-up and Top-down Approaches

Ophthalmology Drugs Market

Data Triangulation

After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Ophthalmology drugs are specifically designed to treat or prevent eye diseases and disorders. These medications target various parts of the eye, including the cornea, conjunctiva, lens, retina, and optic nerve. The market includes a range of effective therapies across different drug modalities, such as biologics and biosimilars (e.g., anti-VEGF drugs, monoclonal antibodies, oligonucleotides, and peptides), small molecules, gene therapy, and cell therapy. These treatments address various conditions, including age-related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema, retinal vein occlusion, uveitis, and neurotrophic keratitis, among others.

Stakeholders

  • Pharmaceutical & biotechnology companies
  • Hospitals
  • Patient advocacy organizations
  • Specialty clinics
  • Long-term care facilities
  • Academic researchers and government research organizations
  • Private research institutes
  • Contract manufacturing organizations (CMOs)
  • Contract research organizations (CROs)
  • Venture capitalists    

Report Objectives

  • To define, describe, and forecast the ophthalmology drugs market by molecule, modality, route of administration, indication, end user, and region
  • To provide detailed information regarding the factors influencing market growth (such as drivers, opportunities, restraints, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall ophthalmology drugs market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To profile the key players in the global ophthalmology drugs market as well as comprehensively analyze their core competencies and market rankings
  • To forecast the size of the market segments in North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
  • To track and analyze competitive developments, such as product launches & approvals, expansions, acquisitions, partnerships, product pipelines, collaborations, and agreements, in the ophthalmology drugs market

 

Previous Versions of this Report

"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Ophthalmology Drugs Market

DMCA.com Protection Status